Le Lézard
Classified in: Health
Subject: ATY

agilon health, inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AGL


NEW YORK, March 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of agilon health, inc. (NYSE: AGL).

Shareholders who purchased shares of AGL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/agilon-health-loss-submission-form/?id=72597&from=4

CLASS PERIOD: January 9, 2019 to January 9, 2024

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) touting the Company's purported visibility into utilization trends and medical costs; (2) failing to disclose increased medical costs that Agilon had incurred prior to and during the class period due to higher utilization of healthcare by MA patients; (3) falsely stating that its incurred-but-not-reported reserve was adequate; (4) making false and misleading statements about the effectiveness of its business model; (5) issuing overly optimistic financial guidance; and (6) issuing risk disclosures that were materially false and misleading because they characterized adverse facts that had already materialized as mere possibilities.

DEADLINE: May 20, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/agilon-health-loss-submission-form/?id=72597&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of AGL during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is May 20, 2024. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

SOURCE The Gross Law Firm


These press releases may also interest you

at 05:05
Sun Nuclear, a Mirion Medical company, will feature new and enhanced solutions for better Quality Management at the ESTRO Annual Meeting, May 3-6, in Glasgow, Scotland. The Sun Nuclear booth (#930) will highlight demonstrations and insights on the...

at 04:32
According to the latest BCC...

at 03:05
In Q1 2024, LEO Pharma delivered a revenue growth of 13% in constant exchange rates (CER). The dermatology portfolio saw accelerated growth in revenue of 16%. The acquisition of TMB-001 to the treatment of congenital ichthyosis added a late-stage...

at 02:22
Hansa Biopharma AB (publ), ("Hansa" or the "Company") (STO: HNSA) today announced that the company's registered share capital and number of shares and votes have increased through the issue of 10,474,740 new ordinary shares on 12 April 2024, whereby...

at 02:20
Vicore Pharma Holding (STO:VICO) Stockholm, May 3 2024- Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim...

2 mai 2024
The report titled "Muscle Stimulator Market by Technique (Burst Mode Alternating Current, Functional Electrical Stimulation, Interferential), Modality (Handheld, Portable, Table Top), Area, Application, End-User - Global Forecast 2024-2030" is now...



News published on and distributed by: